Hemodialysis patients with coronavirus disease 2019: reduced antibody response.
Adult
Aged
Aged, 80 and over
Antibodies, Viral
/ blood
Biomarkers
/ blood
COVID-19
/ blood
Female
Hospitalization
Host-Pathogen Interactions
Humans
Immunoglobulin G
/ blood
Kidney Diseases
/ diagnosis
Male
Middle Aged
Renal Dialysis
Retrospective Studies
SARS-CoV-2
/ immunology
Severity of Illness Index
Time Factors
Antibody
COVID-19
Hemodialysis
Immune response
SARS-CoV-2
Severe disease
Journal
Clinical and experimental nephrology
ISSN: 1437-7799
Titre abrégé: Clin Exp Nephrol
Pays: Japan
ID NLM: 9709923
Informations de publication
Date de publication:
Feb 2022
Feb 2022
Historique:
received:
27
07
2021
accepted:
30
08
2021
pubmed:
7
9
2021
medline:
27
1
2022
entrez:
6
9
2021
Statut:
ppublish
Résumé
Because patients on maintenance hemodialysis (HD) have an impaired immune response to pathogens, they are at higher risk of severe coronavirus disease 2019 (COVID-19). However, data on antibody production among HD patients with COVID-19 is scarce. Thus, we performed a retrospective cohort study evaluating severe acute respiratory syndrome coronavirus two antibody (SARS-CoV-2) production within 1 month after COVID-19 onset in hospitalized patients on HD. SARS-CoV-2-specific immunoglobulin (Ig) G levels were quantified using an iFlash 3000 Chemiluminescence Immunoassay analyzer (Shenzhen YHLO Biotech Co., Ltd.) to detect IgG antibodies specific for the S1 subunit of the spike protein (IgG-S1). Propensity score matching was used to balance covariate distribution in HD and non-HD patients. From April 2020 to February 2021, antibody testing was performed on 161 hospitalized patients with symptomatic COVID-19. Of them, 34 HD patients were matched to 68 non-HD patients. After propensity score matching, the median levels of IgG-S1 in the HD patients at 7-13 days after symptom onset were significantly lower than in non-HD patients, especially in those with severe disease. Among all patients, those with severe disease produced lower levels of IgG-S1 at 7-13 days compared with non-severe patients. COVID-19 patients with severe disease, especially those undergoing HD, had lower IgG-S1 production in the second week of the disease. Thus, the increased risk of severe COVID-19 in HD patients may be, in part, due to a slow and reduced antibody response.
Sections du résumé
BACKGROUND
BACKGROUND
Because patients on maintenance hemodialysis (HD) have an impaired immune response to pathogens, they are at higher risk of severe coronavirus disease 2019 (COVID-19). However, data on antibody production among HD patients with COVID-19 is scarce. Thus, we performed a retrospective cohort study evaluating severe acute respiratory syndrome coronavirus two antibody (SARS-CoV-2) production within 1 month after COVID-19 onset in hospitalized patients on HD.
METHODS
METHODS
SARS-CoV-2-specific immunoglobulin (Ig) G levels were quantified using an iFlash 3000 Chemiluminescence Immunoassay analyzer (Shenzhen YHLO Biotech Co., Ltd.) to detect IgG antibodies specific for the S1 subunit of the spike protein (IgG-S1). Propensity score matching was used to balance covariate distribution in HD and non-HD patients. From April 2020 to February 2021, antibody testing was performed on 161 hospitalized patients with symptomatic COVID-19. Of them, 34 HD patients were matched to 68 non-HD patients.
RESULTS
RESULTS
After propensity score matching, the median levels of IgG-S1 in the HD patients at 7-13 days after symptom onset were significantly lower than in non-HD patients, especially in those with severe disease. Among all patients, those with severe disease produced lower levels of IgG-S1 at 7-13 days compared with non-severe patients.
CONCLUSION
CONCLUSIONS
COVID-19 patients with severe disease, especially those undergoing HD, had lower IgG-S1 production in the second week of the disease. Thus, the increased risk of severe COVID-19 in HD patients may be, in part, due to a slow and reduced antibody response.
Identifiants
pubmed: 34487276
doi: 10.1007/s10157-021-02130-8
pii: 10.1007/s10157-021-02130-8
pmc: PMC8419388
doi:
Substances chimiques
Antibodies, Viral
0
Biomarkers
0
Immunoglobulin G
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
170-177Informations de copyright
© 2021. Japanese Society of Nephrology.
Références
JAMA. 2020 Feb 25;323(8):709-710
pubmed: 31999307
N Engl J Med. 2020 Oct 29;383(18):1724-1734
pubmed: 32871063
Health Sci Rep. 2022 Apr 13;5(3):e572
pubmed: 35509410
Nat Med. 2021 Jul;27(7):1178-1186
pubmed: 33953384
Int J Infect Dis. 2020 Jul;96:131-135
pubmed: 32376308
JAMA. 2021 Feb 16;325(7):632-644
pubmed: 33475701
Clin J Am Soc Nephrol. 2021 Apr 7;16(4):613-614
pubmed: 33208402
Clin J Am Soc Nephrol. 2008 Sep;3(5):1526-33
pubmed: 18701615
Am J Kidney Dis. 2020 Sep;76(3):440-441
pubmed: 32512038
Sci Rep. 2021 Feb 10;11(1):3455
pubmed: 33568776
Kidney Int. 2020 Dec;98(6):1530-1539
pubmed: 32810523
Nature. 2020 Aug;584(7821):437-442
pubmed: 32555388
Clin Exp Immunol. 2008 Jan;151(1):42-50
pubmed: 18005364
Oncotarget. 2017 Jan 3;8(1):268-284
pubmed: 27902485
Am J Kidney Dis. 2021 May;77(5):748-756.e1
pubmed: 33465417
Nature. 2020 Aug;584(7821):430-436
pubmed: 32640463
Nephrol Dial Transplant. 2020 Nov 1;35(11):1973-1983
pubmed: 33151337